Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models-Reference-Cited by-同舟云学术

Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models

Published:2022-09 Issue: Volume:149 Page:107-118
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Nazarian Shahram,Olad Gholamreza,Abdolhamidi Raziyeh,Motamedi Mohammad Javad,Kazemi Rouhollah,Kordbacheh Emad,Felagari Alireza,Olad Hanieh,Ahmadi Ali,Bahiraee Alireza,Farahani Parisa,Haghighi Leila,Hassani Faezeh,Hajhassan Vahideh,Nadi Mona,Sheikhi Abdolkarim,Salimian Jafar,Amani Jafar

Funder

Baqiyatallah University of Medical Sciences

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference61 articles.

1. Safety and potency of COVIran barekat inactivated vaccine candidate for SARS-CoV-2: a preclinical study;Abdoli;bioRxiv,2021

2. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity;Arunachalam;Nature,2021

3. Neutralizing antiviral B cell responses;Bachmann;Annu. Rev. Immunol.,1997

4. Cloning, purification, and characterization of a non-collagenous anti-angiogenic protein domain from human α1 type IV collagen expressed in Sf9 cells;Boosani;Protein Expr. Purif.,2006

5. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2;Chi;Science,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein;Journal of Immunology Research;2024-05-29

2. Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice;IRAN J IMMUNOL;2024

3. Overview of Nucleocapsid-Targeting Vaccines against COVID-19;Vaccines;2023-12-03

4. Safety and immunogenicity of a recombinant receptor‐binding domain‐based protein subunit vaccine (Noora vaccine™) against COVID‐19 in adults: A randomized, double‐blind, placebo‐controlled, Phase 1 trial;Journal of Medical Virology;2022-09-13